O	0	12	Augmentation
O	13	15	of
B-intervention	16	27	venlafaxine
I-intervention	28	31	and
I-intervention	32	41	selective
I-intervention	42	51	serotonin
I-intervention	52	60	reuptake
I-intervention	61	71	inhibitors
I-intervention	72	76	with
I-intervention	77	85	zolpidem
O	86	94	improves
B-condition	95	100	sleep
I-condition	101	104	and
I-condition	105	112	quality
I-condition	113	115	of
I-condition	116	120	life
O	121	123	in
O	124	130	breast
O	131	137	cancer
O	138	146	patients
O	147	151	with
O	152	155	hot
O	156	163	flashes
O	163	164	:
O	165	166	a
O	167	177	randomized
O	177	178	,
O	179	185	double
O	185	186	-
O	186	191	blind
O	191	192	,
O	193	200	placebo
O	200	201	-
O	201	211	controlled
O	212	217	trial
O	217	218	.

O	219	222	Hot
O	223	230	flashes
O	231	234	are
O	235	236	a
O	237	242	major
O	243	250	quality
O	250	251	-
O	251	253	of
O	253	254	-
O	254	258	life
O	259	264	issue
O	265	268	for
O	269	275	breast
O	276	282	cancer
O	283	292	survivors
O	292	293	,
O	294	306	interrupting
O	307	312	sleep
O	312	313	,
O	314	322	reducing
O	323	330	quality
O	331	333	of
O	334	338	life
O	338	339	,
O	340	343	and
O	344	355	diminishing
O	356	365	treatment
O	366	375	adherence
O	376	378	to
O	379	387	adjuvant
O	388	397	endocrine
O	398	407	therapies
O	407	408	.

O	409	418	Serotonin
O	418	419	-
O	419	433	norepinephrine
O	434	442	reuptake
O	443	453	inhibitors
O	454	455	(
O	455	460	SNRIs
O	460	461	)
O	462	465	and
O	466	475	selective
O	476	485	serotonin
O	486	494	reuptake
O	495	505	inhibitors
O	506	507	(
O	507	512	SSRIs
O	512	513	)
O	514	517	are
O	518	522	used
O	523	529	widely
O	530	533	but
O	534	537	are
O	538	542	only
O	543	552	partially
O	553	562	effective
O	563	566	for
O	567	570	hot
O	571	578	flashes
O	578	579	.

O	580	591	Alternative
O	592	602	strategies
O	603	606	are
O	607	613	needed
O	613	614	.

O	615	617	We
O	618	630	hypothesized
O	631	635	that
O	636	648	augmentation
O	649	651	of
O	652	656	SSRI
O	656	657	/
O	657	661	SNRI
O	662	669	therapy
O	670	674	with
O	675	683	hypnotic
O	684	690	agents
O	691	696	would
O	697	705	optimize
O	706	709	hot
O	710	715	flash
O	716	723	therapy
O	724	726	by
O	727	736	improving
O	737	742	sleep
O	743	746	and
O	747	754	quality
O	755	757	of
O	758	762	life
O	762	763	.

B-eligibility	764	769	Women
I-eligibility	770	774	with
I-eligibility	775	781	breast
I-eligibility	782	788	cancer
I-eligibility	789	791	or
I-eligibility	792	794	at
I-eligibility	795	799	high
I-eligibility	800	804	risk
I-eligibility	805	808	for
I-eligibility	809	819	developing
I-eligibility	820	823	the
I-eligibility	824	831	disease
I-eligibility	832	835	who
I-eligibility	836	839	had
I-eligibility	840	843	hot
I-eligibility	844	851	flashes
I-eligibility	852	854	in
I-eligibility	855	866	association
I-eligibility	867	871	with
I-eligibility	872	881	nocturnal
I-eligibility	882	892	awakenings
O	893	897	were
O	898	908	randomized
O	909	911	to
O	912	918	double
O	918	919	-
O	919	926	blinded
O	927	936	treatment
O	937	941	with
B-intervention	942	950	zolpidem
O	951	953	10
O	954	956	mg
O	957	959	or
B-control	960	967	placebo
O	968	971	for
O	972	973	5
O	974	979	weeks
O	979	980	.

O	981	985	SSRI
O	985	986	/
O	986	990	SNRI
O	991	999	nonusers
O	1000	1001	(
O	1001	1003	81
O	1003	1004	%
O	1004	1005	)
O	1006	1013	started
O	1014	1025	venlafaxine
O	1026	1028	XR
O	1029	1031	75
O	1032	1034	mg
O	1034	1035	/
O	1035	1038	day
O	1039	1051	concurrently
O	1051	1052	,
O	1053	1060	whereas
O	1061	1065	SSRI
O	1065	1066	/
O	1066	1070	SNRI
O	1071	1076	users
O	1077	1086	continued
O	1087	1091	that
O	1092	1099	therapy
O	1099	1100	.

O	1101	1103	We
O	1104	1112	compared
O	1113	1116	the
O	1117	1127	proportion
O	1128	1130	of
O	1131	1141	responders
O	1141	1142	,
O	1143	1150	defined
O	1151	1153	as
O	1154	1159	study
O	1160	1170	completers
O	1171	1175	with
O	1176	1184	improved
O	1185	1195	subjective
O	1196	1201	sleep
O	1202	1209	quality
O	1210	1211	(
O	1211	1221	Pittsburgh
O	1222	1227	Sleep
O	1228	1235	Quality
O	1236	1241	Index
O	1241	1242	)
O	1243	1246	and
O	1246	1247	/
O	1247	1249	or
O	1250	1261	objectively
O	1262	1270	assessed
O	1271	1275	wake
O	1276	1280	time
O	1281	1286	after
O	1287	1292	sleep
O	1293	1298	onset
O	1299	1301	on
O	1302	1312	actigraphy
O	1312	1313	,
O	1314	1321	between
O	1322	1328	groups
O	1328	1329	.

O	1330	1332	Of
B-total-participants	1333	1335	53
O	1336	1341	women
O	1342	1343	(
O	1343	1347	aged
B-age	1348	1350	51
I-age	1351	1352	Â±
I-age	1353	1354	8
I-age	1355	1356	y
O	1356	1357	)
O	1358	1368	randomized
O	1369	1371	to
O	1372	1380	zolpidem
O	1381	1393	augmentation
O	1394	1395	(
O	1395	1396	n
O	1397	1398	=
B-intervention-participants	1399	1401	25
O	1401	1402	)
O	1403	1405	or
O	1406	1413	placebo
O	1414	1426	augmentation
O	1427	1428	(
O	1428	1429	n
O	1430	1431	=
B-control-participants	1432	1434	28
O	1434	1435	)
O	1435	1436	,
B-total-participants	1437	1439	38
O	1440	1449	completed
O	1450	1453	the
O	1454	1462	protocol
O	1463	1464	(
B-intervention-participants	1464	1466	57
I-intervention-participants	1466	1467	%
O	1468	1470	on
O	1471	1478	placebo
O	1478	1479	,
B-control-participants	1480	1482	88
I-control-participants	1482	1483	%
O	1484	1486	on
O	1487	1495	zolpidem
O	1495	1496	)
O	1496	1497	.

O	1498	1502	More
O	1503	1508	women
O	1509	1518	augmented
O	1519	1523	with
O	1524	1532	zolpidem
O	1533	1537	than
O	1538	1545	placebo
O	1546	1550	were
O	1551	1561	responders
O	1562	1564	on
O	1565	1568	the
B-outcome	1569	1574	sleep
I-outcome	1575	1582	outcome
O	1583	1584	(
B-iv-bin-percent	1584	1586	40
I-iv-bin-percent	1586	1587	%
O	1588	1590	vs
B-cv-bin-percent	1591	1593	14
I-cv-bin-percent	1593	1594	%
O	1594	1595	;
O	1596	1597	P
O	1598	1599	=
O	1600	1601	0
O	1601	1602	.
O	1602	1605	035
O	1605	1606	)
O	1606	1607	.

B-outcome	1608	1615	Quality
I-outcome	1616	1618	of
I-outcome	1619	1623	life
O	1624	1632	improved
O	1633	1637	more
O	1638	1642	with
O	1643	1651	zolpidem
O	1652	1656	than
O	1657	1661	with
O	1662	1669	placebo
O	1670	1671	(
O	1671	1672	P
O	1673	1674	=
O	1675	1676	0
O	1676	1677	.
O	1677	1679	01
O	1679	1680	)
O	1680	1681	.

O	1682	1691	Treatment
O	1692	1699	effects
O	1700	1702	on
B-outcome	1703	1706	hot
I-outcome	1707	1714	flashes
O	1715	1718	and
B-outcome	1719	1723	mood
O	1724	1727	did
O	1728	1731	not
O	1732	1738	differ
O	1739	1746	between
O	1747	1753	groups
O	1753	1754	.

O	1755	1767	Augmentation
O	1768	1770	of
O	1771	1775	SSRI
O	1775	1776	/
O	1776	1780	SNRI
O	1781	1785	with
O	1786	1794	zolpidem
O	1795	1803	improves
O	1804	1809	sleep
O	1810	1813	and
O	1814	1821	quality
O	1822	1824	of
O	1825	1829	life
O	1830	1832	in
O	1833	1839	breast
O	1840	1846	cancer
O	1847	1856	survivors
O	1857	1861	with
O	1862	1865	hot
O	1866	1873	flashes
O	1874	1877	and
O	1878	1888	associated
O	1889	1894	sleep
O	1895	1906	disturbance
O	1906	1907	.

O	1908	1914	Adding
O	1915	1916	a
O	1917	1925	hypnotic
O	1926	1931	agent
O	1932	1934	to
O	1935	1937	an
O	1938	1942	SSRI
O	1942	1943	/
O	1943	1947	SNRI
O	1948	1953	helps
O	1954	1959	women
O	1960	1962	to
O	1963	1968	sleep
O	1969	1976	through
O	1977	1986	nighttime
O	1987	1990	hot
O	1991	1998	flashes
O	1998	1999	.

O	2000	2010	Treatments
O	2011	2020	targeting
O	2021	2026	sleep
O	2027	2030	may
O	2031	2033	be
O	2034	2036	an
O	2037	2046	important
O	2047	2059	supplemental
O	2060	2068	strategy
O	2069	2071	to
O	2072	2080	optimize
O	2081	2085	well
O	2085	2086	-
O	2086	2091	being
O	2091	2092	.
